|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.6300 - 0.6799|
|52 Week Range||0.2000 - 2.7150|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations NEW YORK , June 26, 2020 /CNW/ - Virtual Investor Conferences, the ...
Signs Definitive Binding Agreement to Purchase the Equity of a Grower-Processor in Pennsylvania; Solidifies Jushi’s Position in One of the Most Attractive Medical Cannabis.
MINNEAPOLIS , March 10, 2020 /PRNewswire/ -- Vireo Health International, Inc. ("Vireo" or the "Company") (CNSX: VREO; OTCQX: VREOF), the science-focused multi-state cannabis company with active operations in exclusively medical-only markets and licenses in 10 states and the commonwealth of Puerto Rico , today announced it has closed the first tranche of a non-brokered private placement offering (the "Offering") of 13,651,574 units of the Company (the "Units"). The Offering was organized by Executive Chairman Bruce Linton and was authorized at a price per Unit of CAD $0.77 for up to a total amount of U.S. $10,000,000 . "This financing reflects the confidence of the capital markets in the potential growth of sales and margin for Vireo," said Executive Chairman, Bruce Linton .
CB2 chosen to advance application with the US FDA for study on safety and efficacy of cannabis-based topical treatments by leading multistate operator, Vireo. Project marks the start of the clinical trial process for Vireo’s topical creams, lotions and gels to be used by patients for pain management. Company will develop full protocols and manage Investigational New Drug (IND) application on behalf of Vireo and will work with the FDA towards approvals.